CLUSTREL
Seizure clusters are a devastating reality for millions. With CLUSTREL, we are developing a smart therapeutic management platform to provide relief for patients suffering from drug-resistant epilepsy. We are moving from the lab closer to the market to make "Seizure Cluster Relief" a reality.
Learn More
Project Highlights
💡 Innovation
First-of-its-kind drug–delivery platform, leveraging graphene oxide nanotechnology and microelectronics to enable the precise, intra-oral release of rescue medication.
⚡ Technology
The device features a miniature, wireless system encapsulated in a medical-grade biocompatible resin, utilizing an innovative electro-actuation mechanism to deliver precise doses from a replaceable capsule.
🔒 Validation
Supported by the EIC Transition funding, we are executing a rigorous roadmap of preclinical testing—from in vitro cellular models to in vivo pharmacokinetics—to ensure full regulatory compliance and safety for future clinical use.
🌍 Impact
Our mission is to address the urgent needs of the 50 million epilepsy patients worldwide by providing a reliable, user-friendly solution for the millions of people suffering from drug-resistant cluster seizures.
About CLUSTREL
CLUSTREL is an innovative EIC-funded project addressing one of the most urgent challenges in neurology: cluster seizures in drug-resistant epilepsy. Our team is developing a groundbreaking therapeutic management platform that combines advanced nanotechnology, microelectronics, and biomedical engineering.
Seizure clusters represent a devastating escalation of epileptic activity affecting millions of patients worldwide. Those diagnosed with drug-resistant epilepsy face particularly severe consequences, including increased risk of status epilepticus, injury, and Sudden Unexpected Nocturnal Death in Epilepsy (SUDEP).
Our mission is to bridge the gap between laboratory innovation and clinical reality, bringing relief to patients who have exhausted conventional treatment options.
Graphene oxide nanotech with wireless micro-electronics for personalised and precision drug delivery.
Targeted treatment for drug-resistant epilepsy and cluster seizure management.
Addressing the needs of 50+ million epilepsy patients worldwide.
Rigorous preclinical testing ensuring regulatory compliance and safety.